Arcus Biosciences/$RCUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Ticker
$RCUS
Sector
Primary listing
NYSE
Employees
601
Headquarters
Website
RCUS Metrics
BasicAdvanced
$2.7B
-
-$3.29
0.84
-
Price and volume
Market cap
$2.7B
Beta
0.84
52-week high
$26.40
52-week low
$6.50
Average daily volume
1.3M
Financial strength
Current ratio
4.359
Quick ratio
4.316
Long term debt to equity
32.647
Total debt to equity
34.707
Interest coverage (TTM)
-48.25%
Profitability
EBITDA (TTM)
-376
Gross margin (TTM)
-111.74%
Net profit margin (TTM)
-142.91%
Operating margin (TTM)
-156.28%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-21.08%
Return on equity (TTM)
-63.26%
Valuation
Price to revenue (TTM)
9.222
Price to book
4.21
Price to tangible book (TTM)
4.21
Price to free cash flow (TTM)
-4.707
Free cash flow yield (TTM)
-21.25%
Free cash flow per share (TTM)
-4.507
Growth
Revenue change (TTM)
-4.26%
Earnings per share change (TTM)
4.64%
3-year revenue growth (CAGR)
30.16%
3-year earnings per share growth (CAGR)
-3.94%
What the Analysts think about RCUS
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
RCUS Financial Performance
Revenues and expenses
RCUS Earnings Performance
Company profitability
RCUS News
AllArticlesVideos
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire·3 days ago
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire·3 weeks ago
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcus Biosciences stock?
Arcus Biosciences (RCUS) has a market cap of $2.7B as of March 27, 2026.
What is the P/E ratio for Arcus Biosciences stock?
The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of March 27, 2026.
Does Arcus Biosciences stock pay dividends?
No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of March 27, 2026.
When is the next Arcus Biosciences dividend payment date?
Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcus Biosciences?
Arcus Biosciences (RCUS) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.